Caribou BiosciencesCRBU
Market Cap: $155M
About: Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.
Employees: 137
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
9% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 44
9% less funds holding
Funds holding: 150 [Q1] → 137 (-13) [Q2]
15.52% less ownership
Funds ownership: 74.35% [Q1] → 58.83% (-15.52%) [Q2]
33% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 39
50% less funds holding in top 10
Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]
67% less call options, than puts
Call options by funds: $54K | Put options by funds: $163K
75% less capital invested
Capital invested by funds: $345M [Q1] → $87.6M (-$257M) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
HC Wainwright & Co. Robert Burns 40% 1-year accuracy 57 / 144 met price target | 423%upside $9 | Buy Reiterated | 3 Sept 2024 |
HC Wainwright & Co. Robert Burns 40% 1-year accuracy 57 / 144 met price target | 423%upside $9 | Buy Reiterated | 14 Aug 2024 |
RBC Capital Luca Issi 33% 1-year accuracy 16 / 48 met price target | 714%upside $14 | Outperform Reiterated | 7 Aug 2024 |
HC Wainwright & Co. Robert Burns 40% 1-year accuracy 57 / 144 met price target | 423%upside $9 | Buy Reiterated | 17 Jul 2024 |
Financial journalist opinion
Based on 8 articles about CRBU published over the past 30 days